The direct tumour cell targeting (autocrine-blockade) effect of infigratinib, particularly in FP RMS has previously been demonstrated by Milton et al., 2022 (19), who highlighted the importance of FGF7-FGFR2 autocrine signalling in treatment response. Here, FGFR2 is linked to neoplasm.